AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (282.2 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Article | Open Access

The Study on Electrochemical Behaviors of the Interactions between Daunorubicin Hydrochloride and BSA

Jie Liu( )Bo Zhang
Taiyuan City Centre Hospital, Taiyuan, 030009
Show Author Information

Abstract

The Electrochemical behaviors of Daunorubicin hydrochloride, and the interactions between Daunorubicin hydrochloride and BSA, were studied in this paper, with Linear sweep voltammetry and Cyclic voltammety methods. The results showed that, there was a reductive peak at E=-0.66V in the Linear sweep voltammetry of Daunorubicin hydrochloride, on condition of 0.1 mol·L-1Na2SO4, pH 8.5B-R buffer solution. After BSA was introduced, the system peak current reduced. There was a maximal system peak current Δip″, when the concentration of Daunorubicin hydrochloride was 5.0×10-5 mol·L-1. At the range of 5.0×10-8 mol·L-1-1.0×10-4 mol·L-1 of the concentration of BSA, it existed a good linear relation between the reduced valve of the peak current of Daunorubicin hydrochloride and the concentration of BSA. This method can be used in the detection of the concentration of BSA.

References

1

Mayako S, Fadia AK, Kenichi W. Effects of angiotensin Ⅱ receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Inter. J. Cardiol. 2006; 110: 378-385 doi:10.1016/j.ijcard. 2005.08.061

2

Christina L, Linn H, Malin B. Mechanisms of cross-resistance between nucleoside analogues and vincristine or daunorubicin in leukemic cells. Biochem. Biophys. Res.Commun. 2004; 320: 825-832 doi:10.1016/j.bbrc.20 04.06.016

3

Murphy G, Lawrence W J, and Lenhard R. American Society Textbook of clinical oncology. 2nd Edn., Atlanta: American Cance Society. 1995

4

Erdem A, Ozsoz M. Interaction of the anticancer drug epirubicin with DNA. Analytica Chimica Acta 2001; 437: 107-114 doi:10.1016/S0003-2670(01)00942-4

5

Cheng GF, Zhang DM, Ding M, et al. Studies on the interaction of Daunomycin and the specific sequence of DNA. Chem. J. Chin. U. 2003; 24: 1395-1399

6

Madeleine H M, William N J, Beatrice L d’E, et al. DNA-drug interactions: The crystal structure of d(CGATCG) complexed with daunomycin. J. Mol. Biol. 1989; 206: 693-705 doi:10.1016/0022-2836(89)90577-9

7

Haj H T, Salerno M, Priebe W, et al. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA. Chem-Biol. Interact. 2003; 145: 349-358 doi:10.1016 /S0009-2797(03)00061-9

8

Lukawska M, Oszczapowicz I, Jelinska A, et al. Development and Validation of RP-HPLC Method for Determination of Novel Derivatives of Daunorubicin. Chem. Anal. 2009; 54: 907-917

9

Lu H, Yuan G, He Q, et al. Rapid analysis of anthracycline antibiotics doxorubicin and daunorubicin by microchip capillary electrophoresis. Microchem. J. 2009; 92: 170-173 doi:10.1016/j.microc.2009.03.005

10

Celine K, Vanessa T, Juan D R, et al. Mass spectrometric investigation of the DNA-binding properties of an anthracycline with two trisaccharide chains. Arch. Biochem. Biophys. 2008; 477: 348-355 doi:10.1016/j.abb.2008.05.009

11

Erland JF, Ellen F. Kinetics of anthracycline accumulation in multidrug-resistant tumor cells: relationship to drug lipophilicity and serum albumin binding. Biochem. Pharmacol. 1998; 56: 1209-1217 doi:10.1016/S0006-2952(98)00255-X

12

Ni Y, Sua S, and Serge K. Spectrofluorimetric studies on the binding of salicylic acid to bovine serum albumin using warfarin and ibuprofen as site markers with the aid of parallel factor analysis. Anal. Chim. Acta. 2006; 580: 206-215 doi:10.1016/j.aca.2006.07.059

Nano Biomedicine and Engineering
Pages 138-142
Cite this article:
Liu J, Zhang B. The Study on Electrochemical Behaviors of the Interactions between Daunorubicin Hydrochloride and BSA. Nano Biomedicine and Engineering, 2010, 2(2): 138-142. https://doi.org/10.5101/nbe.v2i2.p138-142

383

Views

6

Downloads

4

Crossref

5

Scopus

Altmetrics

Received: 10 June 2010
Accepted: 06 July 2010
Published: 09 July 2010
© 2010 J. Liu et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Return